02 September 2020
Vol 12, Issue 559

About The Cover

Cover image expansion

ONLINE COVER CAR and Driver. Chimeric antigen receptor (CAR) T cells are a cancer immunotherapy engineered to recognize a specific antigen on a tumor surface. CAR T cell therapy can result in damage to healthy cells and/or tumor cells escaping destruction when a convenient target tumor antigen is not available. To address this problem, Park et al. first infected tumors with an oncolytic virus to express the antigen CD19, then delivered CAR T cells recognizing CD19 to destroy these tumors. The image shows a tumor infected with an oncolytic virus (green), with cell nuclei in blue. [CREDIT: A. K. PARK, S.-I. KIM, S. J. PRICEMAN/CITY OF HOPE]